A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy

Trial Profile

A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Eribulin (Primary) ; Gemcitabine; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms EG-PG
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 13 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
    • 02 Jun 2017 Primary endpoint has not been met. (Progression free survival) as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top